<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098006</url>
  </required_header>
  <id_info>
    <org_study_id>113854</org_study_id>
    <nct_id>NCT01098006</nct_id>
  </id_info>
  <brief_title>A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays</brief_title>
  <official_title>A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop and characterize immunological assays on blood
      samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B patients of the following 4 groups will be asked to participate in the
      study:

        -  Group A: Immune tolerant patients

        -  Group B: Hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B patients

        -  Group C: Healthy carriers

        -  Group D: Hepatitis B envelope antigen (HBeAg)-negative chronic hepatitis B patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2010</start_date>
  <completion_date type="Actual">February 20, 2012</completion_date>
  <primary_completion_date type="Actual">February 20, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Cluster of Differentiation 4 (CD4) + Foxhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CD4+Foxp3+ Expressing CD45RA and/or GITR and/or Ki67.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CD4+Foxp3+ Expressing CD45RA and/or CCR7 and/or CD62L.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or TNFR2.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of CD4+ Expressing CD40-L and/or IFNg and/or Interleukin Receptor 2 (IL-2) and/or IL-17 in Fresh Samples.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples.</measure>
    <time_frame>At Day 0</time_frame>
    <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Immunologic Tests</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <description>Blood sampling</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from the subject.

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol.

          -  A male or female between, and including, 18 and 65 years of age at study start.

          -  Evidence of chronic hepatitis B infection as per medical record.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the subject
             has practiced adequate contraception for 30 day prior to study start.

        In addition to these general inclusion criteria, subjects should satisfy ALL specific
        criteria according to the specified group maximum 6 months prior to Visit 1 as per medical
        records:

        Group A: Immune tolerant patients

          -  Viral load: &gt; 2x107 IU/mL of HBV DNA

          -  HBeAg positive

          -  Normal levels of ALT according to lab range Group B: HBeAg positive chronic hepatitis
             B patients

          -  Viral load: &gt; 2x104 IU/mL of HBV DNA

          -  HBeAg positive

          -  Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy Group C:
             Healthy carriers

          -  Viral load: not exceeding 2x103 IU/mL of HBV DNA

          -  HBeAg negative

          -  Normal levels of ALT measured at least twice, at least 3 months apart, during the last
             6 months Group D: HBeAg negative chronic hepatitis B patients

          -  Viral load: &gt; 2x103 IU/mL of HBV DNA

          -  HBeAg negative

          -  Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy

        Exclusion Criteria:

          -  Any hepatitis B specific treatment prior to blood sampling at Visit 1.

          -  Any known clinically significant anaemia or any other condition within 7 days prior to
             study entry (Visit 1) as per medical records that would preclude the drawing of blood
             as described in the protocol.

          -  Receipt of live attenuated vaccines within 30 days preceding the blood sampling at
             Visit 1 and the administration of a pandemic influenza vaccine within 21 days
             preceding the blood sampling at Visit 1.

          -  Receipt of blood products within 120 days prior to study entry (Visit 1).

          -  Receipt of immunoglobulins within 120 days prior to study entry (Visit 1).

          -  Receipt of interferon within 120 days prior to study entry (Visit 1).

          -  Use of any investigational or non-registered product (drug or vaccine) within 30 days
             preceding study start, or planned use during the study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  History of immunosuppressive or immune-mediated disorders including autoimmune
             diseases, human immunodeficiency virus (HIV) infection and hepatitis C infection,
             based on medical history and physical examination (no laboratory testing required).

          -  Pregnant or lactating female.

          -  History of malignancy (unless there has been surgical excision followed by a
             sufficient observation period, of at least 5 years, to give a reasonable assurance of
             sustained cure and which, in the estimate of the investigator, is not likely to recur
             during the study period).

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs (including chloroquine) within six months prior to the blood
             sampling at Visit 1 (for corticosteroids, this will mean prednisone â‰¥10 milligram/day
             (10 mg/day), or equivalent). Inhaled and topical steroids are allowed.

          -  History of type I or type II diabetes mellitus including cases controlled with diet
             alone (a subject with past gestational diabetes is eligible).

          -  History of major congenital defect.

          -  Subjects with a history of, or current, alcohol or substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <results_first_submitted>May 24, 2017</results_first_submitted>
  <results_first_submitted_qc>May 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2017</results_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunological assays</keyword>
  <keyword>Chronic hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="6.0"/>
                    <measurement group_id="B2" value="34.0" spread="14.2"/>
                    <measurement group_id="B3" value="36.9" spread="8.7"/>
                    <measurement group_id="B4" value="39.7" spread="15.1"/>
                    <measurement group_id="B5" value="36.43" spread="11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Geographic Ancestry</title>
              <category_list>
                <category>
                  <title>African heritage/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian-Central/South Asian heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian-East Asian heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-Arabic/North African heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White-Caucasian/European heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other: Kazakstan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other: Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Cluster of Differentiation 4 (CD4) + Foxhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Cluster of Differentiation 4 (CD4) + Foxhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.025" lower_limit="4.53" upper_limit="5.295"/>
                    <measurement group_id="O2" value="6.275" lower_limit="5.07" upper_limit="6.51"/>
                    <measurement group_id="O3" value="4.185" lower_limit="3.39" upper_limit="6.16"/>
                    <measurement group_id="O4" value="4.93" lower_limit="4" upper_limit="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="8.53" upper_limit="28.9"/>
                    <measurement group_id="O2" value="16" lower_limit="9.79" upper_limit="29.1"/>
                    <measurement group_id="O3" value="18" lower_limit="14.4" upper_limit="29.25"/>
                    <measurement group_id="O4" value="16.2" lower_limit="10.4" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+HLADR+ICOS+PD1-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1299" lower_limit="0.0785" upper_limit="1.769"/>
                    <measurement group_id="O2" value="0.0702" lower_limit="0.0001" upper_limit="0.122"/>
                    <measurement group_id="O3" value="0.1755" lower_limit="0.07" upper_limit="0.3"/>
                    <measurement group_id="O4" value="0.113" lower_limit="0.0001" upper_limit="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+HLADR+ICOS-PD1+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1191" lower_limit="0.0001" upper_limit="0.2565"/>
                    <measurement group_id="O2" value="0.119" lower_limit="0.0747" upper_limit="0.134"/>
                    <measurement group_id="O3" value="0.0762" lower_limit="0.03" upper_limit="0.189"/>
                    <measurement group_id="O4" value="0.0885" lower_limit="0.0001" upper_limit="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+HLADR+ICOS-PD1-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9705" lower_limit="0.1534" upper_limit="1.95"/>
                    <measurement group_id="O2" value="0.2905" lower_limit="0.21" upper_limit="0.528"/>
                    <measurement group_id="O3" value="0.51" lower_limit="0.232" upper_limit="0.902"/>
                    <measurement group_id="O4" value="0.388" lower_limit="0.09" upper_limit="0.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+HLADR-ICOS+PD1+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1836" lower_limit="0.0001" upper_limit="0.4805"/>
                    <measurement group_id="O2" value="0.0637" lower_limit="0.0001" upper_limit="0.112"/>
                    <measurement group_id="O3" value="0.106" lower_limit="0.0339" upper_limit="0.227"/>
                    <measurement group_id="O4" value="0.092" lower_limit="0.0675" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+HLADR-ICOS+PD1-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3915" lower_limit="0.1665" upper_limit="0.9885"/>
                    <measurement group_id="O2" value="0.356" lower_limit="0.0747" upper_limit="0.725"/>
                    <measurement group_id="O3" value="0.74" lower_limit="0.244" upper_limit="1.43"/>
                    <measurement group_id="O4" value="0.3185" lower_limit="0.151" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+HLADR-ICOS-PD1+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0723" lower_limit="0.0327" upper_limit="0.1541"/>
                    <measurement group_id="O2" value="0.1245" lower_limit="0.0001" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.0972" lower_limit="0.0001" upper_limit="0.182"/>
                    <measurement group_id="O4" value="0.138" lower_limit="0.07" upper_limit="0.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+HLADR-ICOS-PD1-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="7.605" upper_limit="23.3"/>
                    <measurement group_id="O2" value="14.2" lower_limit="8.82" upper_limit="27.9"/>
                    <measurement group_id="O3" value="15.985" lower_limit="12.7" upper_limit="24.85"/>
                    <measurement group_id="O4" value="14.6" lower_limit="9.04" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-HLADR+ICOS+PD1+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.629" lower_limit="0.1209" upper_limit="1.27"/>
                    <measurement group_id="O2" value="2.48" lower_limit="1.21" upper_limit="3.42"/>
                    <measurement group_id="O3" value="1.85" lower_limit="0.937" upper_limit="2.93"/>
                    <measurement group_id="O4" value="2.03" lower_limit="1.22" upper_limit="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-HLADR+ICOS+PD1-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="7.58" upper_limit="27.7"/>
                    <measurement group_id="O2" value="13.35" lower_limit="9.41" upper_limit="20.7"/>
                    <measurement group_id="O3" value="17.15" lower_limit="11.15" upper_limit="24"/>
                    <measurement group_id="O4" value="14.86" lower_limit="9.81" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-HLADR+ICOS-PD1+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5645" lower_limit="0.0596" upper_limit="2.92"/>
                    <measurement group_id="O2" value="0.478" lower_limit="0.234" upper_limit="1.57"/>
                    <measurement group_id="O3" value="0.651" lower_limit="0.177" upper_limit="0.944"/>
                    <measurement group_id="O4" value="1.03" lower_limit="0.49" upper_limit="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-HLADR+ICOS-PD1-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="7.21" upper_limit="29.4"/>
                    <measurement group_id="O2" value="5.065" lower_limit="3.31" upper_limit="10.4"/>
                    <measurement group_id="O3" value="7.16" lower_limit="4.72" upper_limit="12.7"/>
                    <measurement group_id="O4" value="11.6" lower_limit="4.37" upper_limit="23.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-HLADR-ICOS+PD1+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6269" lower_limit="0.0815" upper_limit="1.82"/>
                    <measurement group_id="O2" value="1.285" lower_limit="0.844" upper_limit="2.17"/>
                    <measurement group_id="O3" value="1.26" lower_limit="0.8" upper_limit="2.14"/>
                    <measurement group_id="O4" value="1.96" lower_limit="0.859" upper_limit="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-HLADR-ICOS+PD1-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" lower_limit="3.48" upper_limit="8.345"/>
                    <measurement group_id="O2" value="9.66" lower_limit="4.71" upper_limit="22.1"/>
                    <measurement group_id="O3" value="10.57" lower_limit="5.955" upper_limit="16.035"/>
                    <measurement group_id="O4" value="9.79" lower_limit="6.84" upper_limit="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-HLADR-ICOS-PD1+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7075" lower_limit="0.2181" upper_limit="6.6895"/>
                    <measurement group_id="O2" value="2.07" lower_limit="1.43" upper_limit="3.45"/>
                    <measurement group_id="O3" value="1.815" lower_limit="0.51" upper_limit="2.88"/>
                    <measurement group_id="O4" value="3.28" lower_limit="1.77" upper_limit="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-HLADR-ICOS-PD1-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.85" lower_limit="21.35" upper_limit="44.5"/>
                    <measurement group_id="O2" value="36.8" lower_limit="23.5" upper_limit="41.9"/>
                    <measurement group_id="O3" value="29.85" lower_limit="24.065" upper_limit="38.4"/>
                    <measurement group_id="O4" value="33.2" lower_limit="22.1" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+HLADR+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" lower_limit="25.025" upper_limit="56"/>
                    <measurement group_id="O2" value="25.75" lower_limit="20.5" upper_limit="35.5"/>
                    <measurement group_id="O3" value="31.65" lower_limit="24.1" upper_limit="40"/>
                    <measurement group_id="O4" value="36.6" lower_limit="19.5" upper_limit="47.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+ICOS+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="16.35" upper_limit="38.1"/>
                    <measurement group_id="O2" value="41.1" lower_limit="18" upper_limit="51.5"/>
                    <measurement group_id="O3" value="33.795" lower_limit="21.6" upper_limit="48.5"/>
                    <measurement group_id="O4" value="35.3" lower_limit="24.3" upper_limit="38.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+PD1+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.505" lower_limit="1.3975" upper_limit="13.225"/>
                    <measurement group_id="O2" value="8.465" lower_limit="7.04" upper_limit="12"/>
                    <measurement group_id="O3" value="6.98" lower_limit="3.57" upper_limit="10.45"/>
                    <measurement group_id="O4" value="9.61" lower_limit="7.08" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+pol FOXP3+CD45RA+HLADR+ICOS+PD1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1167" lower_limit="0.0556" upper_limit="0.46"/>
                    <measurement group_id="O2" value="0.209" lower_limit="0.0804" upper_limit="0.36"/>
                    <measurement group_id="O3" value="0.1645" lower_limit="0.0894" upper_limit="0.25"/>
                    <measurement group_id="O4" value="0.1935" lower_limit="0.0675" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.95" lower_limit="94.7" upper_limit="95.45"/>
                    <measurement group_id="O2" value="93.75" lower_limit="93.6" upper_limit="94.9"/>
                    <measurement group_id="O3" value="95.88" lower_limit="93.8" upper_limit="96.61"/>
                    <measurement group_id="O4" value="95" lower_limit="93.8" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="23.69" upper_limit="41.75"/>
                    <measurement group_id="O2" value="44.3" lower_limit="36.6" upper_limit="57.7"/>
                    <measurement group_id="O3" value="33.9" lower_limit="22.13" upper_limit="41.6"/>
                    <measurement group_id="O4" value="30.2" lower_limit="16.47" upper_limit="41.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+HLADR+ICOS+PD1-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0995" lower_limit="0.046" upper_limit="0.2155"/>
                    <measurement group_id="O2" value="0.1103" lower_limit="0.0519" upper_limit="0.167"/>
                    <measurement group_id="O3" value="0.0853" lower_limit="0.0346" upper_limit="0.1865"/>
                    <measurement group_id="O4" value="0.0297" lower_limit="0.004" upper_limit="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+HLADR+ICOS-PD1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2825" lower_limit="0.127" upper_limit="0.4995"/>
                    <measurement group_id="O2" value="0.1695" lower_limit="0.123" upper_limit="0.369"/>
                    <measurement group_id="O3" value="0.267" lower_limit="0.109" upper_limit="0.983"/>
                    <measurement group_id="O4" value="0.232" lower_limit="0.147" upper_limit="0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+HLADR+ICOS-PD1-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" lower_limit="0.7938" upper_limit="1.68"/>
                    <measurement group_id="O2" value="1.52" lower_limit="0.951" upper_limit="3.3"/>
                    <measurement group_id="O3" value="1.71" lower_limit="0.406" upper_limit="2.805"/>
                    <measurement group_id="O4" value="1.07" lower_limit="0.424" upper_limit="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+HLADR-ICOS+PD1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0895" lower_limit="0.0265" upper_limit="0.346"/>
                    <measurement group_id="O2" value="0.0928" lower_limit="0.0569" upper_limit="0.141"/>
                    <measurement group_id="O3" value="0.0873" lower_limit="0.0413" upper_limit="0.3565"/>
                    <measurement group_id="O4" value="0.0976" lower_limit="0.0273" upper_limit="0.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+HLADR-ICOS+PD1-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="0.6668" upper_limit="3.695"/>
                    <measurement group_id="O2" value="1.84" lower_limit="0.48" upper_limit="3.52"/>
                    <measurement group_id="O3" value="0.973" lower_limit="0.325" upper_limit="2.895"/>
                    <measurement group_id="O4" value="0.357" lower_limit="0.0525" upper_limit="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+HLADR-ICOS-PD1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.174" lower_limit="0.1254" upper_limit="0.3645"/>
                    <measurement group_id="O2" value="0.193" lower_limit="0.0875" upper_limit="1.15"/>
                    <measurement group_id="O3" value="0.2585" lower_limit="0.126" upper_limit="4.37"/>
                    <measurement group_id="O4" value="0.368" lower_limit="0.0837" upper_limit="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+HLADR-ICOS-PD1-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.15" lower_limit="18.68" upper_limit="38"/>
                    <measurement group_id="O2" value="36.95" lower_limit="32" upper_limit="54.5"/>
                    <measurement group_id="O3" value="23.8" lower_limit="10.64" upper_limit="31.75"/>
                    <measurement group_id="O4" value="14.96" lower_limit="4.58" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-HLADR+ICOS+PD1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="0.8255" upper_limit="1.935"/>
                    <measurement group_id="O2" value="0.995" lower_limit="0.469" upper_limit="1.54"/>
                    <measurement group_id="O3" value="1.026" lower_limit="0.3795" upper_limit="1.835"/>
                    <measurement group_id="O4" value="0.994" lower_limit="0.549" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-HLADR+ICOS+PD1-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.515" lower_limit="0.6425" upper_limit="2.11"/>
                    <measurement group_id="O2" value="0.727" lower_limit="0.567" upper_limit="0.903"/>
                    <measurement group_id="O3" value="0.789" lower_limit="0.352" upper_limit="1.51"/>
                    <measurement group_id="O4" value="0.522" lower_limit="0.01" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-HLADR+ICOS-PD1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.065" lower_limit="0.944" upper_limit="1.23"/>
                    <measurement group_id="O2" value="0.8265" lower_limit="0.59" upper_limit="1.28"/>
                    <measurement group_id="O3" value="0.8765" lower_limit="0.3965" upper_limit="2"/>
                    <measurement group_id="O4" value="1.34" lower_limit="0.837" upper_limit="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-HLADR+ICOS-PD1-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.755" lower_limit="1.2135" upper_limit="2.83"/>
                    <measurement group_id="O2" value="0.979" lower_limit="0.571" upper_limit="1.52"/>
                    <measurement group_id="O3" value="1.32" lower_limit="0.591" upper_limit="2.805"/>
                    <measurement group_id="O4" value="0.989" lower_limit="0.07" upper_limit="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-HLADR-ICOS+PD1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.935" lower_limit="1.34" upper_limit="5.78"/>
                    <measurement group_id="O2" value="2.28" lower_limit="1.04" upper_limit="3.28"/>
                    <measurement group_id="O3" value="2.485" lower_limit="1.17" upper_limit="7.05"/>
                    <measurement group_id="O4" value="3.02" lower_limit="1.66" upper_limit="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-HLADR-ICOS+PD1-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.985" lower_limit="4.65" upper_limit="13.555"/>
                    <measurement group_id="O2" value="8.835" lower_limit="3.38" upper_limit="12"/>
                    <measurement group_id="O3" value="7.965" lower_limit="4.25" upper_limit="14"/>
                    <measurement group_id="O4" value="5.95" lower_limit="0.11" upper_limit="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-HLADR-ICOS-PD1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.21" lower_limit="4.49" upper_limit="10.285"/>
                    <measurement group_id="O2" value="6.2" lower_limit="3.88" upper_limit="11.8"/>
                    <measurement group_id="O3" value="7.385" lower_limit="3.62" upper_limit="13.25"/>
                    <measurement group_id="O4" value="14.1" lower_limit="7.07" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-HLADR-ICOS-PD1-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" lower_limit="27.95" upper_limit="54.7"/>
                    <measurement group_id="O2" value="27.95" lower_limit="23.4" upper_limit="40.8"/>
                    <measurement group_id="O3" value="34.8" lower_limit="19.6" upper_limit="43.425"/>
                    <measurement group_id="O4" value="37.7" lower_limit="16.8" upper_limit="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-HLADR+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.845" lower_limit="5.62" upper_limit="9.685"/>
                    <measurement group_id="O2" value="6.22" lower_limit="4.4" upper_limit="7.11"/>
                    <measurement group_id="O3" value="8.66" lower_limit="5.26" upper_limit="10.95"/>
                    <measurement group_id="O4" value="7.65" lower_limit="5.92" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-ICOS+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="8.77" upper_limit="27.3"/>
                    <measurement group_id="O2" value="16.95" lower_limit="11.1" upper_limit="18.5"/>
                    <measurement group_id="O3" value="21.03" lower_limit="8.915" upper_limit="32.525"/>
                    <measurement group_id="O4" value="12.2" lower_limit="8.85" upper_limit="21.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-PD1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="10.565" upper_limit="18"/>
                    <measurement group_id="O2" value="9.895" lower_limit="9.12" upper_limit="21"/>
                    <measurement group_id="O3" value="14.17" lower_limit="8.025" upper_limit="40.88"/>
                    <measurement group_id="O4" value="20.3" lower_limit="13.9" upper_limit="59.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+polypositives FOXP3-CD45RA+HLADR+ICOS+PD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0998" lower_limit="0.0562" upper_limit="0.1525"/>
                    <measurement group_id="O2" value="0.069" lower_limit="0.0394" upper_limit="0.148"/>
                    <measurement group_id="O3" value="0.0689" lower_limit="0.0377" upper_limit="0.2355"/>
                    <measurement group_id="O4" value="0.0431" lower_limit="0.028" upper_limit="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of CD4+Foxp3+ Expressing CD45RA and/or GITR and/or Ki67.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+Foxp3+ Expressing CD45RA and/or GITR and/or Ki67.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.335" lower_limit="3.875" upper_limit="7.105"/>
                    <measurement group_id="O2" value="5.82" lower_limit="5.62" upper_limit="6.8"/>
                    <measurement group_id="O3" value="4.68" lower_limit="3.77" upper_limit="5.97"/>
                    <measurement group_id="O4" value="5.37" lower_limit="4.18" upper_limit="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.85" lower_limit="11.2" upper_limit="22.2"/>
                    <measurement group_id="O2" value="14.8" lower_limit="5.9" upper_limit="32.8"/>
                    <measurement group_id="O3" value="18.2" lower_limit="13.6" upper_limit="27.34"/>
                    <measurement group_id="O4" value="16.5" lower_limit="8.58" upper_limit="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+GITR+KI67-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2955" lower_limit="0.0861" upper_limit="1.1145"/>
                    <measurement group_id="O2" value="0.429" lower_limit="0.211" upper_limit="0.571"/>
                    <measurement group_id="O3" value="0.49" lower_limit="0.269" upper_limit="0.74"/>
                    <measurement group_id="O4" value="0.399" lower_limit="0.288" upper_limit="0.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+GITR-KI67+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0985" lower_limit="0.0663" upper_limit="0.218"/>
                    <measurement group_id="O2" value="0.2085" lower_limit="0.12" upper_limit="0.564"/>
                    <measurement group_id="O3" value="0.234" lower_limit="0.14" upper_limit="0.448"/>
                    <measurement group_id="O4" value="0.267" lower_limit="0.07" upper_limit="0.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+GITR-KI67-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.55" lower_limit="10.75" upper_limit="20.55"/>
                    <measurement group_id="O2" value="13.8" lower_limit="3.9" upper_limit="29.9"/>
                    <measurement group_id="O3" value="17.7" lower_limit="13.1" upper_limit="25.7"/>
                    <measurement group_id="O4" value="15.4" lower_limit="7.34" upper_limit="27.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-GITR+KI67+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" lower_limit="7.055" upper_limit="11.05"/>
                    <measurement group_id="O2" value="8.24" lower_limit="4.47" upper_limit="10.4"/>
                    <measurement group_id="O3" value="8.14" lower_limit="6.32" upper_limit="11.32"/>
                    <measurement group_id="O4" value="7.43" lower_limit="5.09" upper_limit="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-GITR+KI67-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.65" lower_limit="26.5" upper_limit="43.5"/>
                    <measurement group_id="O2" value="33.4" lower_limit="21.6" upper_limit="45.2"/>
                    <measurement group_id="O3" value="27.34" lower_limit="22.3" upper_limit="34.18"/>
                    <measurement group_id="O4" value="28.8" lower_limit="20" upper_limit="36.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-GITR-KI67+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.84" lower_limit="3.44" upper_limit="7.11"/>
                    <measurement group_id="O2" value="3.66" lower_limit="2.58" upper_limit="5.58"/>
                    <measurement group_id="O3" value="4.69" lower_limit="3.88" upper_limit="6.77"/>
                    <measurement group_id="O4" value="4.27" lower_limit="3.67" upper_limit="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-GITR-KI67-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="22.6" upper_limit="45.3"/>
                    <measurement group_id="O2" value="32.3" lower_limit="24.4" upper_limit="36.7"/>
                    <measurement group_id="O3" value="37.1" lower_limit="28.1" upper_limit="42.6"/>
                    <measurement group_id="O4" value="41.4" lower_limit="36" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+GITR+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" lower_limit="34.95" upper_limit="55"/>
                    <measurement group_id="O2" value="49.1" lower_limit="26.5" upper_limit="57.4"/>
                    <measurement group_id="O3" value="38.5" lower_limit="30.51" upper_limit="46"/>
                    <measurement group_id="O4" value="36.9" lower_limit="25.6" upper_limit="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+KI67+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.95" lower_limit="12.25" upper_limit="17.25"/>
                    <measurement group_id="O2" value="14.2" lower_limit="8.14" upper_limit="15.7"/>
                    <measurement group_id="O3" value="13.8" lower_limit="10.89" upper_limit="18.9"/>
                    <measurement group_id="O4" value="12.7" lower_limit="9.49" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+polypos. FOXP3+CD45RA+GITR+KI67</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2685" lower_limit="0.1568" upper_limit="0.4415"/>
                    <measurement group_id="O2" value="0.1855" lower_limit="0.0945" upper_limit="0.42"/>
                    <measurement group_id="O3" value="0.331" lower_limit="0.14" upper_limit="0.53"/>
                    <measurement group_id="O4" value="0.28" lower_limit="0.175" upper_limit="0.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.65" lower_limit="92.85" upper_limit="96.15"/>
                    <measurement group_id="O2" value="94.2" lower_limit="93.3" upper_limit="94.4"/>
                    <measurement group_id="O3" value="95.31" lower_limit="94" upper_limit="96.2"/>
                    <measurement group_id="O4" value="94.65" lower_limit="93.75" upper_limit="95.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.95" lower_limit="42.8" upper_limit="49.25"/>
                    <measurement group_id="O2" value="42.9" lower_limit="29.4" upper_limit="56.5"/>
                    <measurement group_id="O3" value="34.3" lower_limit="26.7" upper_limit="44.3"/>
                    <measurement group_id="O4" value="33.4" lower_limit="24.295" upper_limit="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+GITR+KI67-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6515" lower_limit="0.4665" upper_limit="5.7485"/>
                    <measurement group_id="O2" value="0.567" lower_limit="0.359" upper_limit="0.891"/>
                    <measurement group_id="O3" value="0.609" lower_limit="0.27" upper_limit="2.23"/>
                    <measurement group_id="O4" value="0.563" lower_limit="0.3155" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+GITR-KI67+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.328" lower_limit="0.226" upper_limit="0.393"/>
                    <measurement group_id="O2" value="0.365" lower_limit="0.332" upper_limit="0.685"/>
                    <measurement group_id="O3" value="0.251" lower_limit="0.142" upper_limit="0.404"/>
                    <measurement group_id="O4" value="0.2275" lower_limit="0.166" upper_limit="0.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+GITR-KI67-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.85" lower_limit="36.6" upper_limit="48.25"/>
                    <measurement group_id="O2" value="42.5" lower_limit="27.8" upper_limit="55.2"/>
                    <measurement group_id="O3" value="30.14" lower_limit="14.15" upper_limit="41.1"/>
                    <measurement group_id="O4" value="30.3" lower_limit="19.95" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-GITR+KI67+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0535" lower_limit="0.583" upper_limit="1.38"/>
                    <measurement group_id="O2" value="0.566" lower_limit="0.472" upper_limit="0.974"/>
                    <measurement group_id="O3" value="0.854" lower_limit="0.528" upper_limit="1.46"/>
                    <measurement group_id="O4" value="0.7955" lower_limit="0.5645" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-GITR+KI67-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.35" lower_limit="8.36" upper_limit="19.25"/>
                    <measurement group_id="O2" value="12.6" lower_limit="4.34" upper_limit="15.6"/>
                    <measurement group_id="O3" value="12.94" lower_limit="7.33" upper_limit="16.51"/>
                    <measurement group_id="O4" value="13.225" lower_limit="9.03" upper_limit="14.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-GITR-KI67+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.575" lower_limit="1.405" upper_limit="2.05"/>
                    <measurement group_id="O2" value="1.56" lower_limit="1.25" upper_limit="2.44"/>
                    <measurement group_id="O3" value="1.83" lower_limit="1.29" upper_limit="2.24"/>
                    <measurement group_id="O4" value="1.455" lower_limit="1.053" upper_limit="2.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-GITR-KI67-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="29.1" upper_limit="45.8"/>
                    <measurement group_id="O2" value="43.7" lower_limit="34.3" upper_limit="52.6"/>
                    <measurement group_id="O3" value="49.1" lower_limit="40.7" upper_limit="58.5"/>
                    <measurement group_id="O4" value="50.9" lower_limit="38.55" upper_limit="59.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-GITR+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.05" lower_limit="9.585" upper_limit="26.7"/>
                    <measurement group_id="O2" value="14" lower_limit="5.88" upper_limit="17.1"/>
                    <measurement group_id="O3" value="15.9" lower_limit="8.49" upper_limit="19.72"/>
                    <measurement group_id="O4" value="15.7" lower_limit="10.155" upper_limit="17.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-KI67+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" lower_limit="2.47" upper_limit="3.98"/>
                    <measurement group_id="O2" value="3.42" lower_limit="2.32" upper_limit="4"/>
                    <measurement group_id="O3" value="3.32" lower_limit="2.43" upper_limit="4.57"/>
                    <measurement group_id="O4" value="3.28" lower_limit="2.06" upper_limit="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+polypositives FOXP3-CD45RA+GITR+KI67</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1275" lower_limit="0.0874" upper_limit="0.331"/>
                    <measurement group_id="O2" value="0.0944" lower_limit="0.081" upper_limit="0.162"/>
                    <measurement group_id="O3" value="0.0945" lower_limit="0.049" upper_limit="0.202"/>
                    <measurement group_id="O4" value="0.0901" lower_limit="0.0717" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of CD4+Foxp3+ Expressing CD45RA and/or CCR7 and/or CD62L.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+Foxp3+ Expressing CD45RA and/or CCR7 and/or CD62L.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" lower_limit="3.33" upper_limit="5.14"/>
                    <measurement group_id="O2" value="5.48" lower_limit="4.56" upper_limit="6.07"/>
                    <measurement group_id="O3" value="4.26" lower_limit="3.19" upper_limit="6"/>
                    <measurement group_id="O4" value="4.64" lower_limit="2.87" upper_limit="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CCR7+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.15" lower_limit="38.45" upper_limit="50.9"/>
                    <measurement group_id="O2" value="48.4" lower_limit="35.1" upper_limit="61.1"/>
                    <measurement group_id="O3" value="54.065" lower_limit="43.54" upper_limit="59.75"/>
                    <measurement group_id="O4" value="42.4" lower_limit="29.9" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CCR7+CD45RA+CD62L-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4295" lower_limit="0.1971" upper_limit="0.515"/>
                    <measurement group_id="O2" value="0.2005" lower_limit="0.0747" upper_limit="0.366"/>
                    <measurement group_id="O3" value="0.11" lower_limit="0.0485" upper_limit="0.307"/>
                    <measurement group_id="O4" value="0.105" lower_limit="0.0676" upper_limit="0.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CCR7+CD45RA-CD62L+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.85" lower_limit="21.45" upper_limit="33.35"/>
                    <measurement group_id="O2" value="30.1" lower_limit="22.6" upper_limit="32.6"/>
                    <measurement group_id="O3" value="34.66" lower_limit="27.24" upper_limit="39.24"/>
                    <measurement group_id="O4" value="25.65" lower_limit="21.4" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CCR7+CD45RA-CD62L-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.027" upper_limit="3.11"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.56" upper_limit="4.86"/>
                    <measurement group_id="O3" value="1.88" lower_limit="1.18" upper_limit="2.83"/>
                    <measurement group_id="O4" value="2.065" lower_limit="1.63" upper_limit="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CCR7-CD45RA+CD62L+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.909" lower_limit="0.2809" upper_limit="2.32"/>
                    <measurement group_id="O2" value="0.522" lower_limit="0.224" upper_limit="2.14"/>
                    <measurement group_id="O3" value="0.59" lower_limit="0.315" upper_limit="1.13"/>
                    <measurement group_id="O4" value="0.8925" lower_limit="0.36" upper_limit="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CCR7-CD45RA+CD62L-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0502" lower_limit="0.022" upper_limit="0.0671"/>
                    <measurement group_id="O2" value="0.0732" lower_limit="0.0249" upper_limit="0.142"/>
                    <measurement group_id="O3" value="0.0499" lower_limit="0.0001" upper_limit="0.0805"/>
                    <measurement group_id="O4" value="0.075" lower_limit="0.0277" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CCR7-CD45RA-CD62L+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" lower_limit="34.85" upper_limit="51.85"/>
                    <measurement group_id="O2" value="36.6" lower_limit="31.7" upper_limit="43.5"/>
                    <measurement group_id="O3" value="37.7" lower_limit="32.9" upper_limit="44.35"/>
                    <measurement group_id="O4" value="42.5" lower_limit="32.6" upper_limit="56.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CCR7-CD45RA-CD62L-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="7.19" upper_limit="13.9"/>
                    <measurement group_id="O2" value="13.2" lower_limit="6.19" upper_limit="16.8"/>
                    <measurement group_id="O3" value="6.56" lower_limit="4.805" upper_limit="10.06"/>
                    <measurement group_id="O4" value="8.985" lower_limit="6.93" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="13.5" upper_limit="19.65"/>
                    <measurement group_id="O2" value="14" lower_limit="8.64" upper_limit="31.2"/>
                    <measurement group_id="O3" value="16.95" lower_limit="11.8" upper_limit="23"/>
                    <measurement group_id="O4" value="14.25" lower_limit="8.43" upper_limit="19.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD62L+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.55" lower_limit="82.7" upper_limit="91.05"/>
                    <measurement group_id="O2" value="81.5" lower_limit="77.7" upper_limit="92.2"/>
                    <measurement group_id="O3" value="90.85" lower_limit="87.005" upper_limit="93.45"/>
                    <measurement group_id="O4" value="88.2" lower_limit="78.3" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+pol FOXP3+CCR7+CD45RA+CD62L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.25" lower_limit="11.295" upper_limit="18.4"/>
                    <measurement group_id="O2" value="11.3" lower_limit="5.76" upper_limit="28.6"/>
                    <measurement group_id="O3" value="15.1" lower_limit="11.25" upper_limit="21.4"/>
                    <measurement group_id="O4" value="11.95" lower_limit="6.42" upper_limit="15.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="94.85" upper_limit="96.7"/>
                    <measurement group_id="O2" value="94.4" lower_limit="93.9" upper_limit="95.4"/>
                    <measurement group_id="O3" value="95.73" lower_limit="94" upper_limit="96.8"/>
                    <measurement group_id="O4" value="95.4" lower_limit="94.8" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CCR7+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.2" lower_limit="75.3" upper_limit="84.1"/>
                    <measurement group_id="O2" value="79.5" lower_limit="69.4" upper_limit="91.6"/>
                    <measurement group_id="O3" value="76.1" lower_limit="67.8" upper_limit="83.2"/>
                    <measurement group_id="O4" value="70.8" lower_limit="56.8" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CCR7+CD45RA+CD62L-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4295" lower_limit="0.1966" upper_limit="0.6885"/>
                    <measurement group_id="O2" value="0.474" lower_limit="0.259" upper_limit="0.664"/>
                    <measurement group_id="O3" value="0.305" lower_limit="0.187" upper_limit="0.58"/>
                    <measurement group_id="O4" value="0.272" lower_limit="0.196" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CCR7+CD45RA-CD62L+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" lower_limit="25.45" upper_limit="38.3"/>
                    <measurement group_id="O2" value="26.7" lower_limit="24.5" upper_limit="31.7"/>
                    <measurement group_id="O3" value="34.7" lower_limit="26.7" upper_limit="40.32"/>
                    <measurement group_id="O4" value="33.4" lower_limit="22.7" upper_limit="36.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CCR7+CD45RA-CD62L-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.79" lower_limit="3.915" upper_limit="7.415"/>
                    <measurement group_id="O2" value="4.09" lower_limit="2.86" upper_limit="5.84"/>
                    <measurement group_id="O3" value="4.35" lower_limit="2.5" upper_limit="6.33"/>
                    <measurement group_id="O4" value="5.16" lower_limit="2.4" upper_limit="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CCR7-CD45RA+CD62L+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" lower_limit="0.388" upper_limit="1.485"/>
                    <measurement group_id="O2" value="0.755" lower_limit="0.259" upper_limit="2.1"/>
                    <measurement group_id="O3" value="0.719" lower_limit="0.469" upper_limit="2.36"/>
                    <measurement group_id="O4" value="1.01" lower_limit="0.415" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CCR7-CD45RA+CD62L-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2035" lower_limit="0.594" upper_limit="2.06"/>
                    <measurement group_id="O2" value="1.72" lower_limit="0.688" upper_limit="2.08"/>
                    <measurement group_id="O3" value="0.82" lower_limit="0.466" upper_limit="1.88"/>
                    <measurement group_id="O4" value="0.855" lower_limit="0.34" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CCR7-CD45RA-CD62L+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91" lower_limit="7.115" upper_limit="11.19"/>
                    <measurement group_id="O2" value="6.69" lower_limit="3.54" upper_limit="9.01"/>
                    <measurement group_id="O3" value="8.86" lower_limit="7.11" upper_limit="12.22"/>
                    <measurement group_id="O4" value="10.84" lower_limit="5.57" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CCR7-CD45RA-CD62L-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.795" lower_limit="6.36" upper_limit="11.38"/>
                    <measurement group_id="O2" value="9.79" lower_limit="5.37" upper_limit="14.7"/>
                    <measurement group_id="O3" value="10.54" lower_limit="7.72" upper_limit="15.7"/>
                    <measurement group_id="O4" value="15.5" lower_limit="6.36" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.45" lower_limit="39.4" upper_limit="49.5"/>
                    <measurement group_id="O2" value="47.2" lower_limit="40.3" upper_limit="49.7"/>
                    <measurement group_id="O3" value="38.6" lower_limit="30.79" upper_limit="48.05"/>
                    <measurement group_id="O4" value="33.8" lower_limit="28.3" upper_limit="46.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD62L+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="81.4" upper_limit="85.95"/>
                    <measurement group_id="O2" value="85" lower_limit="77.1" upper_limit="88.7"/>
                    <measurement group_id="O3" value="83.6" lower_limit="76.4" upper_limit="86.3"/>
                    <measurement group_id="O4" value="75.3" lower_limit="72" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+polypositives FOXP3-CCR7+CD45RA+CD62L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.45" lower_limit="37.85" upper_limit="45.65"/>
                    <measurement group_id="O2" value="39.7" lower_limit="23.4" upper_limit="48.2"/>
                    <measurement group_id="O3" value="35.56" lower_limit="26.4" upper_limit="43.2"/>
                    <measurement group_id="O4" value="32.1" lower_limit="21.6" upper_limit="41.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or TNFR2.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or TNFR2.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.375" lower_limit="3.745" upper_limit="6.185"/>
                    <measurement group_id="O2" value="5.68" lower_limit="4.84" upper_limit="6.32"/>
                    <measurement group_id="O3" value="4.415" lower_limit="3.195" upper_limit="5.995"/>
                    <measurement group_id="O4" value="5.32" lower_limit="3.98" upper_limit="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD39+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.25" lower_limit="28.4" upper_limit="52.3"/>
                    <measurement group_id="O2" value="54.7" lower_limit="24.1" upper_limit="65.5"/>
                    <measurement group_id="O3" value="42.2" lower_limit="15.2" upper_limit="54.8"/>
                    <measurement group_id="O4" value="46.9" lower_limit="32.9" upper_limit="63.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD39+CD45RA+TNFR2-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0161"/>
                    <measurement group_id="O2" value="0.0156" lower_limit="0.0001" upper_limit="0.112"/>
                    <measurement group_id="O3" value="0.0381" lower_limit="0.0001" upper_limit="0.0706"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD39+CD45RA-TNFR2+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.55" lower_limit="27.75" upper_limit="49.65"/>
                    <measurement group_id="O2" value="37.3" lower_limit="23.6" upper_limit="63.8"/>
                    <measurement group_id="O3" value="39.85" lower_limit="14.8" upper_limit="50.49"/>
                    <measurement group_id="O4" value="43.3" lower_limit="31.3" upper_limit="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD39+CD45RA-TNFR2-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.133" upper_limit="0.831"/>
                    <measurement group_id="O2" value="0.165" lower_limit="0.12" upper_limit="0.352"/>
                    <measurement group_id="O3" value="0.1915" lower_limit="0.0977" upper_limit="0.6025"/>
                    <measurement group_id="O4" value="0.32" lower_limit="0.155" upper_limit="0.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD39-CD45RA+TNFR2+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="11.47" upper_limit="17.45"/>
                    <measurement group_id="O2" value="11" lower_limit="8.25" upper_limit="24.8"/>
                    <measurement group_id="O3" value="17.075" lower_limit="12.6" upper_limit="21.3"/>
                    <measurement group_id="O4" value="13.12" lower_limit="6.96" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD39-CD45RA+TNFR2-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.009" lower_limit="0.5365" upper_limit="1.325"/>
                    <measurement group_id="O2" value="0.7245" lower_limit="0.497" upper_limit="1.16"/>
                    <measurement group_id="O3" value="0.815" lower_limit="0.48" upper_limit="1.79"/>
                    <measurement group_id="O4" value="0.658" lower_limit="0.155" upper_limit="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD39-CD45RA-TNFR2+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.25" lower_limit="30.15" upper_limit="56.35"/>
                    <measurement group_id="O2" value="25.4" lower_limit="21.9" upper_limit="45.3"/>
                    <measurement group_id="O3" value="37.685" lower_limit="28.4" upper_limit="56.7"/>
                    <measurement group_id="O4" value="32.01" lower_limit="24.4" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD39-CD45RA-TNFR2-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8705" lower_limit="0.7215" upper_limit="1.256"/>
                    <measurement group_id="O2" value="0.6765" lower_limit="0.448" upper_limit="0.776"/>
                    <measurement group_id="O3" value="1.085" lower_limit="0.628" upper_limit="2.16"/>
                    <measurement group_id="O4" value="0.702" lower_limit="0.4" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="13.1" upper_limit="20.05"/>
                    <measurement group_id="O2" value="13.4" lower_limit="9.32" upper_limit="39.3"/>
                    <measurement group_id="O3" value="19.75" lower_limit="15.8" upper_limit="24.5"/>
                    <measurement group_id="O4" value="15.7" lower_limit="8.08" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+TNFR2+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="97.15" upper_limit="98"/>
                    <measurement group_id="O2" value="98.4" lower_limit="98" upper_limit="98.6"/>
                    <measurement group_id="O3" value="97.25" lower_limit="95.7" upper_limit="98.6"/>
                    <measurement group_id="O4" value="97.9" lower_limit="96.2" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+pol FOXP3+CD39+CD45RA+TNFR2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2415" lower_limit="0.509" upper_limit="1.805"/>
                    <measurement group_id="O2" value="1.49" lower_limit="1.09" upper_limit="2.25"/>
                    <measurement group_id="O3" value="1.215" lower_limit="0.47" upper_limit="2.03"/>
                    <measurement group_id="O4" value="0.9295" lower_limit="0.593" upper_limit="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.65" lower_limit="93.8" upper_limit="96.3"/>
                    <measurement group_id="O2" value="94.3" lower_limit="93.7" upper_limit="95.2"/>
                    <measurement group_id="O3" value="95.585" lower_limit="94" upper_limit="96.8"/>
                    <measurement group_id="O4" value="94.7" lower_limit="93.2" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD39+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.395" lower_limit="2.82" upper_limit="4.625"/>
                    <measurement group_id="O2" value="3.93" lower_limit="1.55" upper_limit="5.16"/>
                    <measurement group_id="O3" value="4.015" lower_limit="2.135" upper_limit="5.34"/>
                    <measurement group_id="O4" value="4.83" lower_limit="3.7" upper_limit="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD39+CD45RA+TNFR2-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.828" lower_limit="0.4515" upper_limit="1.41"/>
                    <measurement group_id="O2" value="0.531" lower_limit="0.401" upper_limit="0.698"/>
                    <measurement group_id="O3" value="0.5295" lower_limit="0.352" upper_limit="0.786"/>
                    <measurement group_id="O4" value="0.46" lower_limit="0.31" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD39+CD45RA-TNFR2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.965" lower_limit="0.936" upper_limit="2.65"/>
                    <measurement group_id="O2" value="2.25" lower_limit="0.637" upper_limit="2.91"/>
                    <measurement group_id="O3" value="2.22" lower_limit="0.7095" upper_limit="2.9"/>
                    <measurement group_id="O4" value="3.24" lower_limit="1.85" upper_limit="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD39+CD45RA-TNFR2-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6185" lower_limit="0.3685" upper_limit="0.857"/>
                    <measurement group_id="O2" value="0.754" lower_limit="0.133" upper_limit="0.898"/>
                    <measurement group_id="O3" value="0.6635" lower_limit="0.2125" upper_limit="1.085"/>
                    <measurement group_id="O4" value="0.749" lower_limit="0.547" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD39-CD45RA+TNFR2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="1.79" upper_limit="4.095"/>
                    <measurement group_id="O2" value="2.55" lower_limit="1.7" upper_limit="3.2"/>
                    <measurement group_id="O3" value="3.585" lower_limit="2.115" upper_limit="4.485"/>
                    <measurement group_id="O4" value="3.04" lower_limit="1.41" upper_limit="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD39-CD45RA+TNFR2-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.85" lower_limit="36.5" upper_limit="45.7"/>
                    <measurement group_id="O2" value="40.9" lower_limit="28.4" upper_limit="52.9"/>
                    <measurement group_id="O3" value="36.41" lower_limit="29.9" upper_limit="47.9"/>
                    <measurement group_id="O4" value="29.9" lower_limit="24.3" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD39-CD45RA-TNFR2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="29.3" upper_limit="30.55"/>
                    <measurement group_id="O2" value="29.6" lower_limit="19.6" upper_limit="36.3"/>
                    <measurement group_id="O3" value="32.155" lower_limit="24.21" upper_limit="41.345"/>
                    <measurement group_id="O4" value="38.9" lower_limit="26.2" upper_limit="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD39-CD45RA-TNFR2-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="18.1" upper_limit="26.5"/>
                    <measurement group_id="O2" value="20" lower_limit="16.4" upper_limit="23.1"/>
                    <measurement group_id="O3" value="21.42" lower_limit="18.6" upper_limit="25.3"/>
                    <measurement group_id="O4" value="20.9" lower_limit="17.95" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="40.15" upper_limit="50.6"/>
                    <measurement group_id="O2" value="48" lower_limit="39.8" upper_limit="55.3"/>
                    <measurement group_id="O3" value="41.235" lower_limit="33.795" upper_limit="52.195"/>
                    <measurement group_id="O4" value="33.8" lower_limit="25.6" upper_limit="47.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-TNFR2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.05" lower_limit="33.7" upper_limit="36.4"/>
                    <measurement group_id="O2" value="34.1" lower_limit="24" upper_limit="50.2"/>
                    <measurement group_id="O3" value="39.23" lower_limit="29.55" upper_limit="46.935"/>
                    <measurement group_id="O4" value="45.6" lower_limit="33" upper_limit="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+polypositives FOXP3-CD39+CD45RA+TNFR2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3485" lower_limit="0.209" upper_limit="0.561"/>
                    <measurement group_id="O2" value="0.252" lower_limit="0.173" upper_limit="0.398"/>
                    <measurement group_id="O3" value="0.2795" lower_limit="0.221" upper_limit="0.472"/>
                    <measurement group_id="O4" value="0.336" lower_limit="0.244" upper_limit="0.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.555" lower_limit="1.8151" upper_limit="8.095"/>
                    <measurement group_id="O2" value="6.09" lower_limit="5.17" upper_limit="6.73"/>
                    <measurement group_id="O3" value="4.655" lower_limit="3.38" upper_limit="6.145"/>
                    <measurement group_id="O4" value="5.045" lower_limit="3.23" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="15.8" upper_limit="19.7"/>
                    <measurement group_id="O2" value="17.4" lower_limit="7.16" upper_limit="22.8"/>
                    <measurement group_id="O3" value="18.5" lower_limit="13.01" upper_limit="26.3"/>
                    <measurement group_id="O4" value="16.6" lower_limit="8.81" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+CTLA4+OX40-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.25" upper_limit="1.66"/>
                    <measurement group_id="O2" value="1.75" lower_limit="1.24" upper_limit="2.63"/>
                    <measurement group_id="O3" value="1.32" lower_limit="0.47" upper_limit="2.35"/>
                    <measurement group_id="O4" value="1.09" lower_limit="0.74" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+CTLA4-OX40+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.107" lower_limit="0.0722" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.174" lower_limit="0.106" upper_limit="0.205"/>
                    <measurement group_id="O3" value="0.11" lower_limit="0.06" upper_limit="0.31"/>
                    <measurement group_id="O4" value="0.126" lower_limit="0.06" upper_limit="0.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA+CTLA4-OX40-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="14" upper_limit="17.9"/>
                    <measurement group_id="O2" value="15.2" lower_limit="5.85" upper_limit="20.9"/>
                    <measurement group_id="O3" value="16.1" lower_limit="11.3" upper_limit="23.72"/>
                    <measurement group_id="O4" value="13.2" lower_limit="6.32" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-CTLA4+OX40+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.3" upper_limit="2.53"/>
                    <measurement group_id="O2" value="2.08" lower_limit="1.22" upper_limit="4.04"/>
                    <measurement group_id="O3" value="1.345" lower_limit="0.631" upper_limit="2.13"/>
                    <measurement group_id="O4" value="2.38" lower_limit="0.84" upper_limit="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-CTLA4+OX40-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" lower_limit="25" upper_limit="30.4"/>
                    <measurement group_id="O2" value="41" lower_limit="26.5" upper_limit="47.4"/>
                    <measurement group_id="O3" value="24.5" lower_limit="15.9" upper_limit="38.3"/>
                    <measurement group_id="O4" value="31.7" lower_limit="28.08" upper_limit="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-CTLA4-OX40+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.16" lower_limit="6.28" upper_limit="11.9"/>
                    <measurement group_id="O2" value="1.915" lower_limit="0.872" upper_limit="3.26"/>
                    <measurement group_id="O3" value="1.515" lower_limit="0.62" upper_limit="2.54"/>
                    <measurement group_id="O4" value="1.39" lower_limit="0.586" upper_limit="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD45RA-CTLA4-OX40-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" lower_limit="39.5" upper_limit="47.5"/>
                    <measurement group_id="O2" value="42" lower_limit="26.4" upper_limit="47.3"/>
                    <measurement group_id="O3" value="47.9" lower_limit="39.5" upper_limit="56.2"/>
                    <measurement group_id="O4" value="38.1" lower_limit="32.6" upper_limit="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CTLA4+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="27.9" upper_limit="34.6"/>
                    <measurement group_id="O2" value="45" lower_limit="31.8" upper_limit="53.5"/>
                    <measurement group_id="O3" value="27.5" lower_limit="17.64" upper_limit="40.9"/>
                    <measurement group_id="O4" value="39.3" lower_limit="32.1" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+OX40+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.15" upper_limit="14.7"/>
                    <measurement group_id="O2" value="5.15" lower_limit="2.68" upper_limit="6.51"/>
                    <measurement group_id="O3" value="3.66" lower_limit="1.72" upper_limit="6.15"/>
                    <measurement group_id="O4" value="3.94" lower_limit="2.16" upper_limit="7.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+pol FOXP3+CD45RA+CTLA4+OX40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.188" lower_limit="0.0722" upper_limit="0.364"/>
                    <measurement group_id="O2" value="0.118" lower_limit="0.0709" upper_limit="0.381"/>
                    <measurement group_id="O3" value="0.19" lower_limit="0.0322" upper_limit="0.37"/>
                    <measurement group_id="O4" value="0.283" lower_limit="0.0993" upper_limit="0.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.45" lower_limit="91.9" upper_limit="98.2"/>
                    <measurement group_id="O2" value="93.9" lower_limit="93.3" upper_limit="94.8"/>
                    <measurement group_id="O3" value="95.395" lower_limit="93.85" upper_limit="96.645"/>
                    <measurement group_id="O4" value="94.95" lower_limit="94" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" lower_limit="19.455" upper_limit="52.1"/>
                    <measurement group_id="O2" value="46.4" lower_limit="37.1" upper_limit="53"/>
                    <measurement group_id="O3" value="36.05" lower_limit="24.055" upper_limit="46.25"/>
                    <measurement group_id="O4" value="31.55" lower_limit="22.2" upper_limit="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+CTLA4+OX40-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2755" lower_limit="0.0746" upper_limit="0.411"/>
                    <measurement group_id="O2" value="0.263" lower_limit="0.212" upper_limit="0.456"/>
                    <measurement group_id="O3" value="0.2505" lower_limit="0.0902" upper_limit="0.4915"/>
                    <measurement group_id="O4" value="0.265" lower_limit="0.0806" upper_limit="0.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+CTLA4-OX40+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1715" lower_limit="0.0816" upper_limit="0.1975"/>
                    <measurement group_id="O2" value="0.287" lower_limit="0.128" upper_limit="0.488"/>
                    <measurement group_id="O3" value="0.1645" lower_limit="0.0503" upper_limit="0.5495"/>
                    <measurement group_id="O4" value="0.243" lower_limit="0.11" upper_limit="0.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA+CTLA4-OX40-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.55" lower_limit="18.9001" upper_limit="51.55"/>
                    <measurement group_id="O2" value="46" lower_limit="36.7" upper_limit="52"/>
                    <measurement group_id="O3" value="34.4" lower_limit="23.4" upper_limit="44.55"/>
                    <measurement group_id="O4" value="25.5" lower_limit="18" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-CTLA4+OX40+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.508" lower_limit="0.2425" upper_limit="50.0535"/>
                    <measurement group_id="O2" value="0.242" lower_limit="0.167" upper_limit="0.434"/>
                    <measurement group_id="O3" value="0.2645" lower_limit="0.0736" upper_limit="0.619"/>
                    <measurement group_id="O4" value="0.6175" lower_limit="0.31" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-CTLA4+OX40-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" lower_limit="0.9599" upper_limit="2.865"/>
                    <measurement group_id="O2" value="1.87" lower_limit="1.52" upper_limit="2.54"/>
                    <measurement group_id="O3" value="2.39" lower_limit="1.79" upper_limit="3.34"/>
                    <measurement group_id="O4" value="1.845" lower_limit="1.36" upper_limit="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-CTLA4-OX40+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.035" lower_limit="1.2051" upper_limit="4.495"/>
                    <measurement group_id="O2" value="2.48" lower_limit="0.763" upper_limit="4.36"/>
                    <measurement group_id="O3" value="1.78" lower_limit="0.603" upper_limit="5.855"/>
                    <measurement group_id="O4" value="4.015" lower_limit="1.71" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CD45RA-CTLA4-OX40-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.25" lower_limit="19.5529" upper_limit="49.1"/>
                    <measurement group_id="O2" value="51.4" lower_limit="39.7" upper_limit="58.4"/>
                    <measurement group_id="O3" value="53.05" lower_limit="47" upper_limit="66.8"/>
                    <measurement group_id="O4" value="56.05" lower_limit="51.4" upper_limit="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-CTLA4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.825" lower_limit="2.92" upper_limit="52.015"/>
                    <measurement group_id="O2" value="2.34" lower_limit="2.13" upper_limit="3.62"/>
                    <measurement group_id="O3" value="3.4" lower_limit="2.14" upper_limit="4.52"/>
                    <measurement group_id="O4" value="3.55" lower_limit="2" upper_limit="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3-OX40+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.235" lower_limit="3.5" upper_limit="53.095"/>
                    <measurement group_id="O2" value="3.23" lower_limit="1.34" upper_limit="5.2"/>
                    <measurement group_id="O3" value="2.27" lower_limit="0.858" upper_limit="7.995"/>
                    <measurement group_id="O4" value="5.675" lower_limit="2.65" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+polypositives FOXP3-CD45RA+CTLA4+OX40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0488" lower_limit="0.0392" upper_limit="0.2813"/>
                    <measurement group_id="O2" value="0.0366" lower_limit="0.0252" upper_limit="0.0662"/>
                    <measurement group_id="O3" value="0.0359" lower_limit="0.0195" upper_limit="0.0803"/>
                    <measurement group_id="O4" value="0.0646" lower_limit="0.0349" upper_limit="0.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBc CD4+FOXP3+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.26" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.0001" upper_limit="0.53"/>
                    <measurement group_id="O3" value="0.42" lower_limit="0.07" upper_limit="0.67"/>
                    <measurement group_id="O4" value="0.52" lower_limit="0.12" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3+CD69+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.51" lower_limit="0.08" upper_limit="1.08"/>
                    <measurement group_id="O3" value="0.84" lower_limit="0.0001" upper_limit="2.8"/>
                    <measurement group_id="O4" value="1.0115" lower_limit="0.0001" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3+LAP+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.0001" upper_limit="0.087"/>
                    <measurement group_id="O3" value="0.04" lower_limit="0.0001" upper_limit="0.296"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3+CD69+LAP+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.072"/>
                    <measurement group_id="O3" value="0.082" lower_limit="0.0001" upper_limit="0.32"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3+CD69+LAP-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.55"/>
                    <measurement group_id="O2" value="0.69" lower_limit="0.21" upper_limit="1.14"/>
                    <measurement group_id="O3" value="1.09" lower_limit="0.0001" upper_limit="2.54"/>
                    <measurement group_id="O4" value="0.9815" lower_limit="0.0001" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3+CD69-LAP+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" lower_limit="0.0001" upper_limit="0.597"/>
                    <measurement group_id="O2" value="0.002" lower_limit="0.0001" upper_limit="0.091"/>
                    <measurement group_id="O3" value="0.013" lower_limit="0.0001" upper_limit="0.149"/>
                    <measurement group_id="O4" value="0.0086" lower_limit="0.0001" upper_limit="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3+CD69-LAP-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.3" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.1"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.305" lower_limit="0.0801" upper_limit="0.675"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.0001" upper_limit="0.55"/>
                    <measurement group_id="O3" value="0.0101" lower_limit="0.0001" upper_limit="0.2"/>
                    <measurement group_id="O4" value="0.16" lower_limit="0.0001" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3+CD69+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0101" lower_limit="0.0001" upper_limit="4.135"/>
                    <measurement group_id="O2" value="0.95" lower_limit="0.02" upper_limit="1.29"/>
                    <measurement group_id="O3" value="0.905" lower_limit="0.0451" upper_limit="1.885"/>
                    <measurement group_id="O4" value="0.5315" lower_limit="0.0001" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3+LAP+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.184" lower_limit="0.5501" upper_limit="1.984"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.0001" upper_limit="0.641"/>
                    <measurement group_id="O3" value="0.107" lower_limit="0.0001" upper_limit="0.5965"/>
                    <measurement group_id="O4" value="0.0476" lower_limit="0.0001" upper_limit="0.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3+CD69+LAP+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2201" lower_limit="0.0001" upper_limit="1.395"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.299"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.149"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3+CD69+LAP-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025" lower_limit="0.0751" upper_limit="3.055"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.34" upper_limit="1.31"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.4535" upper_limit="2.2"/>
                    <measurement group_id="O4" value="0.5215" lower_limit="0.0001" upper_limit="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3+CD69-LAP+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5065" lower_limit="0.1731" upper_limit="1.064"/>
                    <measurement group_id="O2" value="0.033" lower_limit="0.0001" upper_limit="0.346"/>
                    <measurement group_id="O3" value="0.0805" lower_limit="0.0001" upper_limit="0.392"/>
                    <measurement group_id="O4" value="0.1335" lower_limit="0.0001" upper_limit="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3+CD69-LAP-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.4501"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.1"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0501"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBc CD4+FOXP3-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3-CD69+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.6246"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.0001" upper_limit="0.22"/>
                    <measurement group_id="O3" value="0.28" lower_limit="0.0001" upper_limit="1.26"/>
                    <measurement group_id="O4" value="0.25" lower_limit="0.053" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3-LAP+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0051" lower_limit="0.0001" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.0001" upper_limit="0.08"/>
                    <measurement group_id="O3" value="0.0345" lower_limit="0.0001" upper_limit="0.147"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3-CD69+LAP+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.037"/>
                    <measurement group_id="O3" value="0.01" lower_limit="0.0001" upper_limit="0.0515"/>
                    <measurement group_id="O4" value="0.0126" lower_limit="0.0001" upper_limit="0.0373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3-CD69+LAP-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.1351" upper_limit="0.828"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.0001" upper_limit="0.27"/>
                    <measurement group_id="O3" value="0.185" lower_limit="0.0001" upper_limit="1.245"/>
                    <measurement group_id="O4" value="0.279" lower_limit="0.078" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3-CD69-LAP+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0672" lower_limit="0.0158" upper_limit="0.1165"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.0001" upper_limit="0.0675"/>
                    <measurement group_id="O3" value="0.0165" lower_limit="0.0001" upper_limit="0.108"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+FOXP3-CD69-LAP-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2501" lower_limit="0.0001" upper_limit="1.25"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.2"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0501"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0001" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.35"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3-CD69+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="1.4146"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.068" lower_limit="0.0001" upper_limit="0.475"/>
                    <measurement group_id="O4" value="0.07" lower_limit="0.0001" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3-LAP+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2251" lower_limit="0.0001" upper_limit="0.555"/>
                    <measurement group_id="O2" value="0.0913" lower_limit="0.0001" upper_limit="0.219"/>
                    <measurement group_id="O3" value="0.0993" lower_limit="0.0001" upper_limit="0.3005"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3-CD69+LAP+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0309"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.044"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0229"/>
                    <measurement group_id="O4" value="0.0057" lower_limit="0.0001" upper_limit="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3-CD69+LAP-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1901" lower_limit="0.0001" upper_limit="1.573"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.011"/>
                    <measurement group_id="O3" value="0.1" lower_limit="0.0001" upper_limit="0.4465"/>
                    <measurement group_id="O4" value="0.087" lower_limit="0.0001" upper_limit="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3-CD69-LAP+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.334" lower_limit="0.0736" upper_limit="0.5597"/>
                    <measurement group_id="O2" value="0.173" lower_limit="0.0001" upper_limit="0.208"/>
                    <measurement group_id="O3" value="0.1011" lower_limit="0.0001" upper_limit="0.2795"/>
                    <measurement group_id="O4" value="0.046" lower_limit="0.0001" upper_limit="0.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+FOXP3-CD69-LAP-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.0501" upper_limit="1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0001" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.1"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+FOXP3+CD69+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.2301"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.62"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.0001" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+LAP+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.1671"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.067"/>
                    <measurement group_id="O4" value="0.29" lower_limit="0.0001" upper_limit="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD69+LAP+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.1915"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.014"/>
                    <measurement group_id="O4" value="0.259" lower_limit="0.01" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD69+LAP-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0351"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.67"/>
                    <measurement group_id="O4" value="0.2" lower_limit="0.0001" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+FOXP3+CD69-LAP+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.74" upper_limit="0.74"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.055" lower_limit="0.0001" upper_limit="0.25"/>
                    <measurement group_id="O4" value="0.06" lower_limit="0.0001" upper_limit="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of CD4+ Expressing CD40-L and/or IFNg and/or Interleukin Receptor 2 (IL-2) and/or IL-17 in Fresh Samples.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+ Expressing CD40-L and/or IFNg and/or Interleukin Receptor 2 (IL-2) and/or IL-17 in Fresh Samples.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBc CD4+CD40L+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0181" lower_limit="0.0056" upper_limit="0.0294"/>
                    <measurement group_id="O2" value="0.0032" lower_limit="0.0001" upper_limit="0.0209"/>
                    <measurement group_id="O3" value="0.0013" lower_limit="0.0001" upper_limit="0.0255"/>
                    <measurement group_id="O4" value="0.0135" lower_limit="0.0001" upper_limit="0.0271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+IFNg+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0164" lower_limit="0.0001" upper_limit="0.038"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+IL2+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0044" lower_limit="0.0001" upper_limit="0.0255"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0023"/>
                    <measurement group_id="O3" value="0.0014" lower_limit="0.0001" upper_limit="0.012"/>
                    <measurement group_id="O4" value="0.0004" lower_limit="0.0001" upper_limit="0.0066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0128" lower_limit="0.0015" upper_limit="0.0277"/>
                    <measurement group_id="O2" value="0.0025" lower_limit="0.0001" upper_limit="0.009"/>
                    <measurement group_id="O3" value="0.0004" lower_limit="0.0001" upper_limit="0.0043"/>
                    <measurement group_id="O4" value="0.0014" lower_limit="0.0001" upper_limit="0.0089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0017"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2-IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2-IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0018" lower_limit="0.0007" upper_limit="0.003"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0018"/>
                    <measurement group_id="O3" value="0.0025" lower_limit="0.0001" upper_limit="0.0066"/>
                    <measurement group_id="O4" value="0.0011" lower_limit="0.0001" upper_limit="0.0036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2-IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0024"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.002"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2-IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0158" lower_limit="0.0051" upper_limit="0.026"/>
                    <measurement group_id="O2" value="0.0023" lower_limit="0.0001" upper_limit="0.0122"/>
                    <measurement group_id="O3" value="0.0013" lower_limit="0.0001" upper_limit="0.0216"/>
                    <measurement group_id="O4" value="0.0113" lower_limit="0.0001" upper_limit="0.0259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2+IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0038" lower_limit="0.0001" upper_limit="0.024"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2+IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0017"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2-IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0088"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2-IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0023" lower_limit="0.0001" upper_limit="0.0072"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2+IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0012"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2+IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0013"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0002"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.002"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2-IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0006" lower_limit="0.0001" upper_limit="0.0015"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0018"/>
                    <measurement group_id="O3" value="0.0012" lower_limit="0.0001" upper_limit="0.0054"/>
                    <measurement group_id="O4" value="0.0022" lower_limit="0.0001" upper_limit="0.0036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0051"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0062"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0127"/>
                    <measurement group_id="O4" value="0.0053" lower_limit="0.0001" upper_limit="0.0207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+IFNg+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0011" lower_limit="0.0001" upper_limit="0.0143"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+IL2+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0049" lower_limit="0.0001" upper_limit="0.011"/>
                    <measurement group_id="O2" value="0.0064" lower_limit="0.0001" upper_limit="0.0191"/>
                    <measurement group_id="O3" value="0.0021" lower_limit="0.0001" upper_limit="0.0151"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0013" lower_limit="0.0001" upper_limit="0.0165"/>
                    <measurement group_id="O2" value="0.0058" lower_limit="0.0001" upper_limit="0.0486"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0024"/>
                    <measurement group_id="O4" value="0.0002" lower_limit="0.0001" upper_limit="0.0061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+IL2+IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+IL2+IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+IL2-IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+IL2-IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+IL2+IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0013"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+IL2+IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0007"/>
                    <measurement group_id="O2" value="0.0015" lower_limit="0.0001" upper_limit="0.0038"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0028"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+IL2-IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0007"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+IL2-IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0051"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0095"/>
                    <measurement group_id="O4" value="0.0041" lower_limit="0.0001" upper_limit="0.0181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L-IL2+IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0025" lower_limit="0.0001" upper_limit="0.0075"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L-IL2+IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L-IL2-IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0068"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L-IL2-IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0015"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L-IL2+IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0036"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.004"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L-IL2+IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0044"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0143"/>
                    <measurement group_id="O3" value="0.0017" lower_limit="0.0001" upper_limit="0.0108"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L-IL2-IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0019" lower_limit="0.0001" upper_limit="0.004"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0021"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBc CD8+CD40L+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" lower_limit="0.002" upper_limit="0.0071"/>
                    <measurement group_id="O2" value="0.0034" lower_limit="0.0001" upper_limit="0.0106"/>
                    <measurement group_id="O3" value="0.0002" lower_limit="0.0001" upper_limit="0.0128"/>
                    <measurement group_id="O4" value="0.0065" lower_limit="0.0001" upper_limit="0.0098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+IFNg+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0346" lower_limit="0.0197" upper_limit="0.0609"/>
                    <measurement group_id="O2" value="0.003" lower_limit="0.0001" upper_limit="0.0117"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0048"/>
                    <measurement group_id="O4" value="0.0003" lower_limit="0.0001" upper_limit="0.0197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+IL2+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0053"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0052"/>
                    <measurement group_id="O4" value="0.001" lower_limit="0.0001" upper_limit="0.0101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0153"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0345"/>
                    <measurement group_id="O3" value="0.0021" lower_limit="0.0001" upper_limit="0.0523"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0005"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2+IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2-IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0016"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2-IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0017"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2+IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2+IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0016"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2-IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2-IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0039" lower_limit="0.002" upper_limit="0.007"/>
                    <measurement group_id="O2" value="0.0052" lower_limit="0.0001" upper_limit="0.0106"/>
                    <measurement group_id="O3" value="0.0002" lower_limit="0.0001" upper_limit="0.0126"/>
                    <measurement group_id="O4" value="0.0066" lower_limit="0.0001" upper_limit="0.0111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2+IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0005"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0034"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2+IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2-IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0034" lower_limit="0.0001" upper_limit="0.0155"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2-IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0251" lower_limit="0.0115" upper_limit="0.0548"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0097"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0048"/>
                    <measurement group_id="O4" value="0.0008" lower_limit="0.0001" upper_limit="0.0113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2+IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2+IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0035"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2-IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="57"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0025"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.004"/>
                    <measurement group_id="O3" value="0.0021" lower_limit="0.0001" upper_limit="0.045"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0046" lower_limit="0.0005" upper_limit="0.009"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0057"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0118"/>
                    <measurement group_id="O4" value="0.0002" lower_limit="0.0001" upper_limit="0.0073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+IFNg+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0167" lower_limit="0.0087" upper_limit="0.0324"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0064"/>
                    <measurement group_id="O3" value="0.0027" lower_limit="0.0001" upper_limit="0.0155"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+IL2+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.011"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.031"/>
                    <measurement group_id="O3" value="0.0013" lower_limit="0.0001" upper_limit="0.0066"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0158"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0448"/>
                    <measurement group_id="O3" value="0.0015" lower_limit="0.0001" upper_limit="0.0462"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD4+CD40L+IL2+IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0026"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L+IL2+IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L+IL2-IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L+IL2-IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0019"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L+IL2+IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L+IL2+IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0017" lower_limit="0.0001" upper_limit="0.0074"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0003"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L+IL2-IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L+IL2-IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0046" lower_limit="0.0005" upper_limit="0.0083"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0083"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0106"/>
                    <measurement group_id="O4" value="0.0002" lower_limit="0.0001" upper_limit="0.0038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L-IL2+IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0139"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L-IL2+IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L-IL2-IFNg+IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0016" lower_limit="0.0001" upper_limit="0.0035"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0038"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L-IL2-IFNg+IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0126" lower_limit="0.0056" upper_limit="0.0198"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0067"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0126"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L-IL2+IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0019"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0019"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L-IL2+IFNg-IL17-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0041"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0066"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBs CD8+CD40L-IL2-IFNg-IL17+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.029"/>
                    <measurement group_id="O3" value="0.0026" lower_limit="0.0001" upper_limit="0.0446"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBc CD4+CD40L+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0048" lower_limit="0.0001" upper_limit="0.0095"/>
                    <measurement group_id="O2" value="0.108" lower_limit="0.0148" upper_limit="0.337"/>
                    <measurement group_id="O3" value="0.0336" lower_limit="0.0001" upper_limit="0.2448"/>
                    <measurement group_id="O4" value="0.032" lower_limit="0.0001" upper_limit="0.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+IFNg+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0099"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0097"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+IL2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0161" lower_limit="0.0001" upper_limit="0.0321"/>
                    <measurement group_id="O2" value="0.0128" lower_limit="0.0001" upper_limit="0.0486"/>
                    <measurement group_id="O3" value="0.0033" lower_limit="0.0001" upper_limit="0.0245"/>
                    <measurement group_id="O4" value="0.0083" lower_limit="0.0001" upper_limit="0.0368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0063" lower_limit="0.0001" upper_limit="0.0124"/>
                    <measurement group_id="O2" value="0.0012" lower_limit="0.0001" upper_limit="0.0046"/>
                    <measurement group_id="O3" value="0.0047" lower_limit="0.0002" upper_limit="0.0154"/>
                    <measurement group_id="O4" value="0.0037" lower_limit="0.0007" upper_limit="0.0139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg+IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2-IFNg+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2-IFNg+IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0014"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg-IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg-IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0009"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2-IFNg-IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2-IFNg-IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0048" lower_limit="0.0001" upper_limit="0.0095"/>
                    <measurement group_id="O2" value="0.105" lower_limit="0.0148" upper_limit="0.347"/>
                    <measurement group_id="O3" value="0.031" lower_limit="0.0001" upper_limit="0.2438"/>
                    <measurement group_id="O4" value="0.031" lower_limit="0.0001" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2+IFNg+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2+IFNg+IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0008"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2-IFNg+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2-IFNg+IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0085"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0095"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2+IFNg-IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2+IFNg-IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0161" lower_limit="0.0001" upper_limit="0.0321"/>
                    <measurement group_id="O2" value="0.0104" lower_limit="0.0001" upper_limit="0.0522"/>
                    <measurement group_id="O3" value="0.0022" lower_limit="0.0001" upper_limit="0.0213"/>
                    <measurement group_id="O4" value="0.0083" lower_limit="0.0001" upper_limit="0.0348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L-IL2-IFNg-IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0063" lower_limit="0.0001" upper_limit="0.0124"/>
                    <measurement group_id="O2" value="0.0012" lower_limit="0.0001" upper_limit="0.0057"/>
                    <measurement group_id="O3" value="0.0048" lower_limit="0.0001" upper_limit="0.0158"/>
                    <measurement group_id="O4" value="0.0039" lower_limit="0.0007" upper_limit="0.0139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples.</title>
        <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
        <time_frame>At Day 0</time_frame>
        <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples.</title>
          <description>The frequency was assessed based on the following range of markers: CD4, CD25, CD45RA, CD45RO, ICOS, CD39, tumor necrosis factor receptor 2 (TNFR2), HLA-DR, PD-1, chemokine receptor 7 (CCR7), CD62L, OX40, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), anti-Foxp3 and Ki67.</description>
          <population>The analysis was performed on the According-to-protocol (ATP) cohort for immunogenicity, which included all subjects who met all eligibility criteria, with a blood sample available and who had satisfied all specific criteria according to their specific group.</population>
          <units>Treg cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBc CD8+CD40L+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0556" lower_limit="0.0001" upper_limit="0.1472"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0265"/>
                    <measurement group_id="O4" value="0.0035" lower_limit="0.0001" upper_limit="0.0193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+IFNg+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0246" lower_limit="0.0127" upper_limit="0.0365"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0239"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0248"/>
                    <measurement group_id="O4" value="0.0002" lower_limit="0.0001" upper_limit="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+IL2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0448" lower_limit="0.0078" upper_limit="0.0819"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0195"/>
                    <measurement group_id="O3" value="0.0004" lower_limit="0.0001" upper_limit="0.015"/>
                    <measurement group_id="O4" value="0.0042" lower_limit="0.0001" upper_limit="0.0105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1191" lower_limit="0.0001" upper_limit="0.238"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0768"/>
                    <measurement group_id="O3" value="0.0058" lower_limit="0.0001" upper_limit="0.0716"/>
                    <measurement group_id="O4" value="0.0075" lower_limit="0.0001" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD4+CD40L+IL2+IFNg+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2+IFNg+IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2-IFNg+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2-IFNg+IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2+IFNg-IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2+IFNg-IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2-IFNg-IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L+IL2-IFNg-IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0556" lower_limit="0.0001" upper_limit="0.1554"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0277"/>
                    <measurement group_id="O4" value="0.0035" lower_limit="0.0001" upper_limit="0.0193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2+IFNg+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2+IFNg+IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0011"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2-IFNg+IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2-IFNg+IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0246" lower_limit="0.0127" upper_limit="0.0365"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0227"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0217"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2+IFNg-IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O3" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                    <measurement group_id="O4" value="0.0001" lower_limit="0.0001" upper_limit="0.0001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2+IFNg-IL17-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0448" lower_limit="0.0078" upper_limit="0.0819"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0109"/>
                    <measurement group_id="O3" value="0.0053" lower_limit="0.0001" upper_limit="0.0153"/>
                    <measurement group_id="O4" value="0.0002" lower_limit="0.0001" upper_limit="0.0088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBc CD8+CD40L-IL2-IFNg-IL17+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1166" lower_limit="0.0001" upper_limit="0.233"/>
                    <measurement group_id="O2" value="0.0001" lower_limit="0.0001" upper_limit="0.0768"/>
                    <measurement group_id="O3" value="0.0058" lower_limit="0.0001" upper_limit="0.0761"/>
                    <measurement group_id="O4" value="0.0075" lower_limit="0.0001" upper_limit="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B virus (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with active inflammation and varying degrees of liver fibrosis.</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

